When it comes to weight loss, most treatments focus purely on the number on the scales. But Wegovy® (semaglutide) is different. This innovative GLP-1 injection doesn’t just help you lose weight — it’s now also clinically proven to help protect your heart and improve your long-term health.
Wegovy® is the only GLP-1 medication approved by the MHRA (Medicines and Healthcare products Regulatory Agency) in the UK for both weight management and cardiovascular risk reduction in people who are overweight or living with obesity and have established heart disease.
What is Wegovy®?
Wegovy® is a prescription-only medication that contains semaglutide, a type of medicine known as a GLP-1 receptor agonist. It works by mimicking a natural hormone in your body that helps regulate appetite and blood sugar.
By helping you feel fuller for longer and reducing cravings, Wegovy® makes it easier to eat less — supporting significant, sustainable weight loss when combined with a balanced diet and regular physical activity.
Wegovy® can help you achieve clinically significant weight reduction — often greater than 15% of your starting weight.
The Heart Health Connection
Recent research has shown that losing weight with Wegovy® offers more than just aesthetic or lifestyle benefits — it can also have a major impact on cardiovascular health.
In a landmark clinical trial involving thousands of participants with excess weight and existing heart disease, Wegovy® reduced the risk of serious heart-related events — including heart attack, stroke, and cardiovascular death — by up to 20%.
This means Wegovy® doesn’t just help you look better and feel better — it can help you live longer.
Key Benefits of Wegovy®
✅ Proven Weight Loss:
In clinical studies, people taking Wegovy® lost significantly more weight than those using lifestyle changes alone — with many losing over 15% of their body weight.
❤️ Supports Heart Health:
Wegovy® is now recognised for its role in reducing the risk of major cardiovascular events in people living with overweight or obesity and heart disease.
💪 Improves Overall Health:
Weight loss achieved with Wegovy® can help improve blood pressure, cholesterol levels, and blood sugar control — all of which support long-term wellness.
⏳ Helps You Live Longer:
By lowering cardiovascular risks and improving metabolic health, Wegovy® can contribute to a longer, healthier life.
Who Can Use Wegovy®?
Wegovy® is suitable for adults who are:
- Living with obesity (BMI ≥ 30), or
- Overweight (BMI ≥ 27) with weight-related health conditions such as high blood pressure, type 2 diabetes, or high cholesterol.
It is not suitable for everyone, so it’s important to complete a medical questionnaire on our website and book in for a video consultation before starting treatment. Our doctor prescriber will review your medical history and decide whether Wegovy® is right for you.
How to Start Wegovy®
At WebMed Pharmacy, we make it simple and discreet to start your Wegovy® journey. Our online consultation process ensures you get personalised medical advice and a prescription if suitable.
Your Wegovy® treatment comes in a convenient once-weekly injection pen, designed for ease of use at home. The dose starts low and is gradually increased to minimise side effects and help your body adjust.
Why Choose WebMed Pharmacy for Wegovy® in the UK?
At WebMed Pharmacy, we make it safe, convenient, and discreet to start your Wegovy® treatment online.
✅ GPhC regulated & CQC approved pharmacy
✅ GMC registered doctor prescribers
✅ Fast, discreet delivery to your door
✅ Ongoing medical support throughout your journey
✅ Confidential online consultation
✅ Saturday morning coaching – Free of Charge!
Your health and safety come first — always.
Start Your Wegovy® Journey Today
Wegovy® is more than just a weight loss treatment — it’s a step towards a healthier heart, longer life, and improved quality of living.
Take control of your health today.
Talk to WebMed Pharmacy about Wegovy® — the treatment that helps you do more than lose weight.
💚 Do more than lose weight — protect your heart and your future.
Bibliography
1. Summary of Product Characteristics (SmPC) Wegovy 0.25 mg
Novo Nordisk Limited. (n.d.). Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC). Retrieved October 30, 2025, from https://www.medicines.org.uk/emc/product/13799/smpc
2. Journal article: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes by A. M. Lincoff et al.
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., Ryan, D. H., & SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221-2232. https://doi.org/10.1056/NEJMoa2307563
Author: Margaret Hudson MRPharmS